A Novel PD-L1-targeting Antagonistic DNA Aptamer With Antitumor Effects

Molecular Therapy - Nucleic Acids - Tập 5 - Trang e397 - 2016
Wei‐Yun Lai1,2, Bo-Tsang Huang2, Jen-Wei Wang1,2, Pei-Ying Lin2,3, Pan‐Chyr Yang4,2
1Aptamer Core Facility, Institute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan
2Institute of Biomedical Sciences, Academia Sinica, Taipei Taiwan
3National Center of Excellence for Clinical Trials and Research Center, Department of Medical Research, National Taiwan University Hospital, Taipei, Taiwan
4Department of Internal Medicine, National Taiwan University Hospital and College of Medicine, Taipei, Taiwan

Tóm tắt

Từ khóa


Tài liệu tham khảo

Sharma, 2015, Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential, Cell, 161, 205, 10.1016/j.cell.2015.03.030

Domling, 2014, Programmed death-1: therapeutic success after more than 100 years of cancer immunotherapy, Angew Chem Int Ed, 53, 2286, 10.1002/anie.201307906

Smyth, 2016, Combination cancer immunotherapies tailored to the tumour microenvironment, Nat Rev Clin Oncol, 13, 143, 10.1038/nrclinonc.2015.209

Okazaki, 2013, A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical application, Nat Immunol, 14, 1212, 10.1038/ni.2762

Herbst, 2014, Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients, Nature, 515, 563, 10.1038/nature14011

Okazaki, 2007, PD-1 and PD-1 ligands: from discovery to clinical application, Int Immunol, 19, 813, 10.1093/intimm/dxm057

Callahan, 2013, At the bedside: CTLA-4- and PD-1-blocking antibodies in cancer immunotherapy, J Leukoc Biol, 94, 41, 10.1189/jlb.1212631

Intlekofer, 2013, At the bench: preclinical rationale for CTLA-4 and PD-1 blockade as cancer immunotherapy, J Leukoc Biol, 94, 25, 10.1189/jlb.1212621

Samaranayake, 2009, Challenges in monoclonal antibody-based therapies, Ann Med, 41, 322, 10.1080/07853890802698842

Prodeus, 2015, Targeting the PD-1/PD-L1 immune evasion axis with DNA aptamers as a novel therapeutic strategy for the treatment of disseminated cancers, Mol Ther Nucleic Acids, 4, e237, 10.1038/mtna.2015.11

Mayer, 2009, The chemical biology of aptamers, Angew Chem Int Ed, 48, 2672, 10.1002/anie.200804643

Lao, 2015, Aptamer nanomedicine for cancer therapeutics: barriers and potential for translation, ACS Nano, 9, 2235, 10.1021/nn507494p

Sun, 2014, Oligonucleotide aptamers: new tools for targeted cancer therapy, Mol Ther Nucleic Acids, 3, e182, 10.1038/mtna.2014.32

Dollins, 2008, Aptamers in immunotherapy, Hum Gene Ther, 19, 443, 10.1089/hum.2008.045

Gilboa, 2013, Use of oligonucleotide aptamer ligands to modulate the function of immune receptors, Clin Cancer Res, 19, 1054, 10.1158/1078-0432.CCR-12-2067

Xiang, 2015, Nucleic acid aptamer-guided cancer therapeutics and diagnostics: the next generation of cancer medicine, Theranostics, 5, 23, 10.7150/thno.10202

Ng, 2006, Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease, Nat Rev Drug Discov, 5, 123, 10.1038/nrd1955

Kato, 2016, Structural basis for specific inhibition of Autotaxin by a DNA aptamer, Nat Struct Mol Biol, 23, 395, 10.1038/nsmb.3200

Chen, 2011, IL-17RA aptamer-mediated repression of IL-6 inhibits synovium inflammation in a murine model of osteoarthritis, Osteoarthritis Cartilage, 19, 711, 10.1016/j.joca.2011.01.018

Wheeler, 2011, Inhibition of HIV transmission in human cervicovaginal explants and humanized mice using CD4 aptamer-siRNA chimeras, J Clin Invest, 121, 2401, 10.1172/JCI45876

Ozer, 2014, New technologies provide quantum changes in the scale, speed, and success of SELEX methods and aptamer characterization, Mol Ther Nucleic Acids, 3, e183, 10.1038/mtna.2014.34

Blind, 2015, Aptamer selection technology and recent advances, Mol Ther Nucleic Acids, 4, e223, 10.1038/mtna.2014.74

Alam, 2015, FASTAptamer: a bioinformatic toolkit for high-throughput sequence analysis of combinatorial selections, Mol Ther Nucleic Acids, 4, e230, 10.1038/mtna.2015.4

Li, 2015, The EMBL-EBI bioinformatics web and programmatic tools framework, Nucleic Acids Res, 43, W580, 10.1093/nar/gkv279

Lin, 2008, The PD-1/PD-L1 complex resembles the antigen-binding Fv domains of antibodies and T cell receptors, Proc Natl Acad Sci USA, 105, 3011, 10.1073/pnas.0712278105

Chow, 2014, Chemokines in cancer, Cancer Immunol Res, 2, 1125, 10.1158/2326-6066.CIR-14-0160

Groom, 2011, CXCR3 in T cell function, Exp Cell Res, 317, 620, 10.1016/j.yexcr.2010.12.017

Singh, 2007, Chemokines in tumor angiogenesis and metastasis, Cancer Metastasis Rev, 26, 453, 10.1007/s10555-007-9068-9

Zuker, 2003, Mfold web server for nucleic acid folding and hybridization prediction, Nucleic Acids Res, 31, 3406, 10.1093/nar/gkg595

Popenda, 2012, Automated 3D structure composition for large RNAs, Nucleic Acids Res, 40, e112, 10.1093/nar/gks339

Duhovny, 2002, Efficient unbound docking of rigid molecules, Lect Notes Comput Sc, 2452, 185, 10.1007/3-540-45784-4_14

Schneidman-Duhovny, 2005, PatchDock and SymmDock: servers for rigid and symmetric docking, Nucleic Acids Res, 33, W363, 10.1093/nar/gki481

Schindelin, 2015, The ImageJ ecosystem: an open platform for biomedical image analysis, Mol Reprod Dev, 82, 518, 10.1002/mrd.22489

Schindelin, 2012, Fiji: an open-source platform for biological-image analysis, Nat Methods, 9, 676, 10.1038/nmeth.2019

Pachynski, 2015, Evaluation of tumor-infiltrating leukocyte subsets in a subcutaneous tumor model, J Vis Exp, 98, e52657